FDA Review and Study Data Lift Insmed Stock
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares https://t.co/BCRJAUwGIJ $INSM + 7% $SRPT $SNY $GSK #biotech
RBC Flags Revolution, Xenon, Arrowhead as Top Biotech Takeover Targets
RBC: Revolution, Xenon, Arrowhead among top #biotech takeover targets https://t.co/h1toH9szrU by @realJacobBell $ARWR $XENE $RVMD $DYNE
Excalipoint Secures $69M for Next‑Gen T‑Cell Engagers
Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers https://t.co/809RqRWJNL by @gwendolynawu #biotech #startups
Bicycle Cuts 30% Staff, Abandons Padcev Challenger
Bicycle to lay off 30% of staff, pivot away from Padcev challenger https://t.co/m3JFu2mwoB @ByJonGardner $BCYC $PFE $MRK
Pfizer's Ibrance Successor Advances with Fresh Study Data
Pfizer’s Ibrance successor moves forward with new study data https://t.co/ozXAZYmc3M by Kristin Jensen $PFE $LLY $NVS $RHHBY $ONC
R1 Secures $78M to Advance Kidney Drug Development
R1 starts up with $78M, aiming for a better kidney drug https://t.co/PQQjX47ODM by @gwendolynawu #biotecjh #startups
CytomX Jumps 66% on Promising Colorectal ADC Data
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer https://t.co/PxQMISvyri by @Lilah_Alvarado $CTMX + 66%
Structure's GLP-1 Pill Shows Best-in-Class Obesity Results
Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial https://t.co/j0fzAg6GRV @ByJonGardner $GPCR $LLY $NVO $AZN $MRK #obesity
Sarepta Tests Elevidys Safety, Sana
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy https://t.co/hkixuANCCV $SRPT $SANA $INO $BAYRY #biotech
China Biotech Receives FDA Approval for First Cell Therapy Trial
With FDA go ahead, a China #biotech notches a first in cell therapy testing https://t.co/QorwJmou8w by @realJacobBell $XENE $BHVN
Biotech Layoffs Hit Evotec, Vistagen; Immutep Shares Plunge
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure https://t.co/OikmCdJ6sg $EVO $VTGN $IMMP - 81% $RARE $ATRA
Lilly Warns GLP‑1 Knockoffs Are Dangerous, Intensifies Compounder Battle
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders https://t.co/XOKLqIzAES @ByJonGardner $LLY $NVO #obesity
Vima Raises $100M to Develop Oral Movement Disorder Drug
With $100M, Vima pursues an oral drug for movement disorders https://t.co/gLrhlYDMSy by @gwendolynawu #biotech #startups
BioNTech Founders Leave to Launch New mRNA Venture
BioNTech founders to step down and helm new mRNA startup https://t.co/yjvsVRQH2D by @Lilah_Alvarado $BNTX - 20%
Xenon Scores Epilepsy Win; FDA Revives Duchenne Cell Therapy Review
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy https://t.co/l40xYeW2Xh $XENE $CAPR + 15% $REGN $PFE $ABBV $GSK #biotech
Bristol Myers Reports Positive Results for Next‑Gen Blood Cancer Drug
Bristol Myers claims success in study of another next-gen blood cancer drug https://t.co/fqPbZ2Szv8 by @gwendolynawu $BMY
UniQure Sparks Gene Therapy Rally After Prasad Departs
UniQure leads genetic medicine biotech rally after news of Prasad’s exit https://t.co/zu1CtJfj29 by @realJacobBell $QURE $RGNX $ATRA $LXEO #GeneTherapy
Roche, Zealand Stocks Tumble After Bland Obesity Drug Data
Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results https://t.co/5pSR2vcHBD by @Lilah_Alvarado $RHHBY $ZEAL $LLY $NVO #obesity
Servier Spends $2.5B to Expand Cancer Pipeline
Servier to build cancer drug pipeline with $2.5B purchase of Day One https://t.co/aH0z8jt9tr by @realJacobBell $DAWN #biotech
Eli Lilly Courts Employers to Expand Obesity Drug Access
Lilly targets employers in new bid to broaden access to obesity drugs https://t.co/Y6fmcmTcf1 @ByJonGardner $LLY $NVO #obesity
Blackstone Invests $400M in Teva, Sanofi Gut Drug
Blackstone puts $400M into Teva, Sanofi gut disease drug https://t.co/CkxPaI6CPr @ByJonGardner $TEVA $SNY $MRK $RHHBY
Pierre Fabre Pushes to Revive US Cell Therapy Approval
Pierre Fabre seeks to revive US approval chances for spurned cell therapy https://t.co/gJeklT8asd @ByJonGardner $ATRA $QURE $RGNX
Roche's MS Drug Shows Promise, Approval Still Uncertain
Roche pill succeeds in another MS study, but approval questions linger https://t.co/JY8uZCI5iA @ByJonGardner $RHHBY $SNY
FDA Demands Extra Study for UniQure's Huntington Gene Therapy
UniQure says FDA wants another study of Huntington’s gene therapy https://t.co/1pgFDoE2V9 by @realJacobBell $QURE - 35% #GeneTherapy #Huntingtonsdisease
Aardvark Pauses Pivotal Prader‑Willi Trial over Safety
Safety concerns spur Aardvark to halt key Prader-Willi drug trial https://t.co/PWkOuDMIvo $AARD - 52% $SLNO
Atrium Launches to Tackle Rare Heart Diseases with RNA
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA https://t.co/xLp2oQDHGy $RNA $NVS #startups
Biotech IPOs Surge with $400M Offering
New: Generate caps a strong month for #biotech IPOs with $400M offering https://t.co/HzslZOPcwM by @gwendolynawu $GENB $AZN $AMGN #IPO
Novo's Vivtex Deal Could Unlock Superior Oral Obesity Meds
With Vivtex deal, Novo gains a chance at better oral obesity drugs https://t.co/DhIelbC9jI by @gwendolynawu $NVO #obesity
Vir Surges After Astellas Partnership and T‑cell Data
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager https://t.co/336c9FJdjt by @Lilah_Alvarado $VIR + 27% $JANX $ALPMY
Novo Slashes GLP‑1 Prices; Palvella Spikes on Data
Novo to cut GLP-1 drug prices; Palvella soars on study data https://t.co/UAs4IETgPX $NVO $PVLA+ 32% $GOSS $VNDA $PFE #biotech
Novo Highlights New Data on Triple‑Target Obesity Therapy
Novo, searching for a spark, spotlights new data for three-pronged obesity drug https://t.co/pPo9Oc1wlF $NVO $LLY #obesity
Slate Secures $130M, Launches Chinese Headache Drug
Slate starts up with $130M and a headache drug from China https://t.co/6DEltQAI8s by @gwendolynawu #biotech #startups $HLUBF
Madrigal Slides as Ex-Novartis Exec Joins Daiichi
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi https://t.co/ymSJ5qY8kq $MDGL $NVS $JNJ $ACIU #biotech
Altesa Secures $75M for Lung Drug, Led by Ex‑Trump Official
Altesa, run by former Trump official, raises $75M for well-traveled lung drug https://t.co/bUx5dcvNJy by @gwendolynawu #biotech #startups
FDA Proposes Single Pivotal Trial as Approval Standard
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals https://t.co/ADRb1miphf by Kristin Jensen #biotech
Biotech Earnings: Neurocrine Drops, Alnylam Faces Skepticism
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor https://t.co/kU1ex80A24 by @realJacobBell $NBIX - 10% $ALNY - 4% $ASND - 2% $BBIO #biotech
Seres Cuts Staff and Pauses Flagship Program
Seres to lay off staff, pause top program in latest reboot https://t.co/yJRtypSN3d by @Lilah_Alvarado $MCRB - 37%
Sanofi Appoints Ex-Merck KGaA Chief Garijo as CEO
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo https://t.co/SDLUYOzPuD by Kristin Jensen $SNY - 4% $MKKGY
